Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection. It is not yet known whether heparin is more effective than M-EDTA in preventing catheter-related infections and blockages in patients at high risk for a catheter-related infection.

PURPOSE: This randomized clinical trial is studying heparin to see how well it works compared with M-EDTA in preventing catheter-related infections and blockages in patients at high risk for a catheter-related infection.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Calcium heparin; Edetic Acid; Heparin; Minocycline; Pentetic Acid; Pharmaceutical Solutions

Criteria

DISEASE CHARACTERISTICS:

• At high risk of acquiring a catheter infection, as evidenced by any of the following:

• Diagnosis of leukemia, lymphoma, myeloma, or melanoma-sarcoma

• Undergoing hematopoietic stem cell transplantation

• Receiving aldesleukin

• Pediatric cancer patients

• New (≤ 10 days old) functioning externalized tunneled or nontunneled central venous catheter (CVC), such as a Hickman/Broviac or Hohn catheter, or peripherally inserted central venous catheter (PICC) utilized for infusion of chemotherapy, blood and blood products, or other intermittent infusions

• No occluded CVC

• No existing local or systemic catheter infection

• More than 3 days since removal of a prior CVC due to an infection

• No externalized CVC that is projected to remain in place for < 2 weeks

• No infusion ports or Groshong catheters

• No coated CVC impregnated with an antimicrobial or antiseptic agent

PATIENT CHARACTERISTICS:

• Life expectancy ≥ 3 months

• No history of allergy to any tetracycline

• No contraindication to flush solution dwell time of ≥ 4 hours

• No hypocalcemia while receiving calcium supplementation through the catheter

• Not pregnant or nursing

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics